Azad A.A., Eigl B.J., Leibowitz-Amit R., Lester R., Kollmannsberger C., Murray N., Clayton R., Heng D.Y.C., Joshua A.M., Chi K.N.
European Urology 2015 67:3 (441-447)
Background Although abiraterone acetate (abiraterone) has proven efficacy in two randomised phase 3 trials in metastatic castration-resistant prostate cancer (mCRPC), patients who had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ?2 were either excluded or under-represented in these trials. Objective To compare outcomes in ECOG PS 0-1 and ?2 in mCRPC patients treated with abiraterone. Design, setting, and participants Cancer registries from three Canadian centres were used to retrospectively identify mCRPC patients (postdocetaxel and docetaxel-naïve) treated with abiraterone. ECOG PS, clinicopathologic characteristics, prostate-specific antigen (PSA) response, and survival data were collected. Outcome measurements and statistical analysis Survival outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards modelling was used to examine the effect of clinicopathologic characteristics on overall survival (OS) and time to PSA progression. Results and limitations A total of 519 patients were identified; 61% (n = 318) and 39% (n = 201) were ECOG PS 0-1 and ?2, respectively. ECOG PS 0-1 patients were significantly more likely than PS ?2 patients to achieve a PSA decline ?50% from…(vermás)